FDA approves Novo Nordisk’s Wegovy weight-loss pill; $NVO jumps and $LLY faces new oral-GLP-1 competition

Reuters reports the FDA approved Novo Nordisk’s Wegovy weight-loss pill, making Novo the first to market with a potent oral obesity drug. Novo shares jumped (including the US-listed ADR), while Eli Lilly traded roughly flat as investors weighed how fast Lilly can catch up with its own oral contender.

Why it matters for stocks

Pills broaden the obesity market: a meaningful slice of patients don’t want injections, so an effective pill can expand total demand.

First-mover advantage: Novo gets an early window to capture “pill-preference” patients before competing oral drugs arrive (Lilly’s orforglipron is widely expected to be next, potentially in 2026).

Pricing/access narrative: Reuters notes a Novembe ...